The Prostate. Supplement最新文献_第10页

Critical evaluation of transurethral resection and incision of the prostate. 经尿道前列腺切除术的临床评价。

The Prostate. Supplement Pub Date : 1990-01-01 DOI: 10.1002/pros.2990170504

R C Bruskewitz, M M Christensen

引用次数: 34

Role of balloon dilation in the treatment of benign prostatic hyperplasia. 球囊扩张在治疗良性前列腺增生中的作用。

The Prostate. Supplement Pub Date : 1990-01-01 DOI: 10.1002/pros.2990170505

P K Reddy

引用次数: 18

Medical outcomes research and benign prostatic hyperplasia. 医学成果研究与良性前列腺增生。

The Prostate. Supplement Pub Date : 1990-01-01 DOI: 10.1002/pros.2990170507

M J Barry

引用次数: 61

Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. 良性前列腺增生的自然病史在药物干预评价中的重要性。

The Prostate. Supplement Pub Date : 1990-01-01 DOI: 10.1002/pros.2990170502

J T Isaacs

{"title":"Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention.","authors":"J T Isaacs","doi":"10.1002/pros.2990170502","DOIUrl":"https://doi.org/10.1002/pros.2990170502","url":null,"abstract":"The variable natural history of untreated symptomatic benign prostatic hyperplasia (BPH) and the fact that therapeutic intervention is based more on subjective than objective criteria of progressive disease have important consequences for appropriately evaluating the effects of pharmacologic intervention on clinical BPH. To evaluate accurately the success of drug therapy for symptomatic BPH, any trial must include a placebo treatment arm for comparison. However, for such a placebo control to be legitimate, it must not affect the natural history of BPH. To evaluate the effect of placebo treatment on BPH, a large body of data following the natural history of untreated clinical BPH from a variety of independent studies was combined and compared to those from a large variety of independent studies in which a placebo-treated group of patients with clinical BPH also followed. These comparisons demonstrate that 1) placebo treatment does not affect the natural history of the disease; 2) spontaneous improvement usually occurs within the first 6 months of initial presentation of symptoms, if it is to occur at all; and 3) 3-6 months of follow-up are needed to determine if a patient is going to get worse. Thus, to evaluate accurately the potential benefit of any medical intervention for symptomatic BPH, placebo-controlled clinical trials will be required and should be of at least 6 month's duration.","PeriodicalId":77436,"journal":{"name":"The Prostate. Supplement","volume":"3 ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pros.2990170502","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12854381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 124

New approaches in the treatment of benign prostatic hyperplasia. Proceedings of the Urological Association. May 6, 1989, Dallas, Texas. 治疗良性前列腺增生的新途径。泌尿外科学会会刊。1989年5月6日，德克萨斯州达拉斯。

The Prostate. Supplement Pub Date : 1990-01-01

引用次数: 0

Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. 肾上腺素能阻滞剂在治疗良性前列腺增生中的作用。

The Prostate. Supplement Pub Date : 1990-01-01 DOI: 10.1002/pros.2990170508

H Lepor

{"title":"Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia.","authors":"H Lepor","doi":"10.1002/pros.2990170508","DOIUrl":"https://doi.org/10.1002/pros.2990170508","url":null,"abstract":"The dynamic component of infravesical obstruction in men with symptomatic benign prostatic hyperplasia (BPH) is determined by alpha 1-adrenoceptor-mediated contractions of the prostatic capsule, prostate adenoma, and bladder neck. Since alpha 1-adrenoceptors are sparse in the bladder, medical therapy aimed at blocking the alpha receptor will relieve bladder outlet obstruction without inhibiting bladder function. Numerous clinical studies have evaluated the use of various alpha blockers for the treatment of BPH. Although the majority of these trials involved limited numbers of patients treated for only short periods, their results have consistently shown that alpha blockers improve urinary flow rates. Adverse reactions appear to be more frequent and more serious with the use of nonselective alpha blockers than with selective alpha 1 blockers, such as terazosin or prazosin. Terazosin offers the additional advantage of once-daily dosing. The common association of hypertension, hyperlipidemia, and symptomatic BPH in the aging male population may provide further impetus for initiating treatment with alpha blockers because alpha blockers are effective antihypertensive agents and may favorably alter lipid profiles.","PeriodicalId":77436,"journal":{"name":"The Prostate. Supplement","volume":"3 ","pages":"75-84"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pros.2990170508","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12854387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 84

Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial. 每日一次特拉唑嗪治疗良性前列腺增生的疗效:一项随机、双盲安慰剂对照临床试验。

The Prostate. Supplement Pub Date : 1990-01-01 DOI: 10.1002/pros.2990170509

P G Fabricius, P Weizert, U Dunzendorfer, J M Hannaford, C Maurath

{"title":"Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial.","authors":"P G Fabricius, P Weizert, U Dunzendorfer, J M Hannaford, C Maurath","doi":"10.1002/pros.2990170509","DOIUrl":"https://doi.org/10.1002/pros.2990170509","url":null,"abstract":"This randomized, placebo-controlled, double-blind study was performed to evaluate the efficacy and safety of once-a-day terazosin (10 mg/day) in ambulatory patients (n = 57) with benign prostatic hyperplasia (BPH). After a 4-week placebo lead-in and a 24-week treatment period with terazosin (both single-blind), 30 patients who responded to terazosin were randomly assigned to either the terazosin or placebo treatment group for 12 weeks. During the single-blind treatment period, the peak urine flow rate increased 54% from a baseline average of 7.76 ml/sec to 11.92 ml/sec after terazosin; the mean flow rate increased 55% from a baseline of 4.90 ml/sec to 7.59 ml/sec; and the residual volume decreased 56% from 93.1 ml to 40.7 ml. The mean obstructive symptom score, irritative symptom score and physician's global assessment score improved by 68%, 34% and 27%, respectively. All these changes were significant (P less than 0.05) when compared to baseline values. During the double-blind period, the improvement in all the variables was sustained in the terazosin group but not in the placebo group. Peak and mean urinary flow rates, and physician's global assessment showed significant (P less than or equal to 0.05) differences at the end of the double-blind period. Adverse events occurred only during the single-blind period. The most frequent were headache (n = 6), asthenia (n = 3), and hypotension (n = 3). In summary, terazosin administered once-a-day improved the obstructive and irritative symptoms of BPH, urine flow rates and residual volume. Terazosin was well tolerated.","PeriodicalId":77436,"journal":{"name":"The Prostate. Supplement","volume":"3 ","pages":"85-93"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pros.2990170509","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12854388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 69

Medical management of benign prostatic hyperplasia with androgen suppression. 良性前列腺增生伴雄激素抑制的医学处理。

The Prostate. Supplement Pub Date : 1990-01-01 DOI: 10.1002/pros.2990170506

J D McConnell

引用次数: 54

Effect of bladder outlet obstruction on the morphology, physiology, and pharmacology of the bladder. 膀胱出口梗阻对膀胱形态学、生理学和药理学的影响。

The Prostate. Supplement Pub Date : 1990-01-01 DOI: 10.1002/pros.2990170503

R M Levin, P A Longhurst, F C Monson, K Kato, A J Wein

{"title":"Effect of bladder outlet obstruction on the morphology, physiology, and pharmacology of the bladder.","authors":"R M Levin, P A Longhurst, F C Monson, K Kato, A J Wein","doi":"10.1002/pros.2990170503","DOIUrl":"https://doi.org/10.1002/pros.2990170503","url":null,"abstract":"Bladder outlet obstruction secondary to benign prostatic hyperplasia induces numerous changes in bladder morphology, physiology, and pharmacology. These changes have been studied experimentally in various animal models, and while each species has advantages and disadvantages, it is unclear which is most like man. It has been shown that tissue hypertrophy leading to an increase in tissue mass develops rapidly after bladder outlet obstruction. Ischemia induced by the obstruction results in acute muscle dysfunction. The degree of functional impairment is directly related to the degree of tissue hypertrophy. However, the bladder contractile apparatus appears to have a surprising regenerative ability, such that recovery of bladder function becomes obvious 14 days after obstruction. Urodynamic changes include an increase in urinary frequency and voiding pressure and a decrease in voided volume. Clinically, involuntary bladder contractions are often present. Determination of which of these specific aspects of outlet obstruction the investigator is interested in studying will dictate the selection of the most appropriate animal model.","PeriodicalId":77436,"journal":{"name":"The Prostate. Supplement","volume":"3 ","pages":"9-26"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pros.2990170503","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12853753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 164

Urodynamics in benign prostatic hyperplasia: a survey. 良性前列腺增生的尿动力学研究。

The Prostate. Supplement Pub Date : 1989-01-01 DOI: 10.1002/pros.2990150508

T Hald

引用次数: 131